Fundz

Retension Pharmaceuticals reported raising $12.3 Million in an initial SEC Form D filing, from an offering of $20 Million

PUBLIC · RTSNMay 06, 2025$12.3M of $20M raised

Amount Raised

$12.3 Million

$12.3 Million sold, per SEC Form D (first sale Apr 22, 2025)

Round Type

Venture

McleanBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Who to call at Retension Pharmaceuticals, and when

A new round usually means Retension Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Retension Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Retension Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Retension Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Retension Pharmaceuticals

Location

Mclean, Virginia, United States

About

Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Retension Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Retension Pharmaceuticals's next move

See what Strategic adds

Retension Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.